BCRX

Biocryst Pharmaceuticals Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.

Did you know?

BCRX's revenue grew at a 61.8% CAGR over the last 6 years.

Current Price

$9.19

+0.33%

Profile

Valuation (TTM)

Market Cap$1.93B

P/E7.33

EV—

P/B—

Shares Out210.54M

P/Sales2.21

Revenue$874.84M

EV/EBITDA6.15

Biocryst Pharmaceuticals Inc (BCRX) Dividends

Dividend Overview

Dividend Yield

—

Dividend / Share

—

Key Metrics

Market Cap

$1.93B

P/E Ratio

7.33

Forward P/E

—

EPS

$1.21

PEG Ratio

-0.01

Book Value

$-0.57

Dividend Yield

—

Profit Margin

30.16%

ROE

—

Dividend History

Dividend Safety

BCRX Dividend Analysis

Biocryst Pharmaceuticals Inc (BCRX) dividend analysis including yield, payout history, and sustainability metrics.

P/E ratio: 7.33. Profit margin: 30.16%. Free cash flow: $344.90M. This page shows Biocryst Pharmaceuticals Inc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.

GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Biocryst Pharmaceuticals Inc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.